Perioperative chemotherapy with nivolumab for HER2-negative locally advanced gastric cancer: a case series
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
Perioperative chemotherapy with nivolumab for HER2-negative locally advanced gastric cancer: a case series ; volume:10 ; number:1 ; day:28 ; month:8 ; year:2024 ; pages:1-9 ; date:12.2024
Surgical case reports ; 10, Heft 1 (28.8.2024), 1-9, 12.2024
- Creator
-
Toji, Yuta
Takeuchi, Shintaro
Ebihara, Yuma
Kurashima, Yo
Harada, Kazuaki
Hayashi, Mariko
Abe, Hirotake
Wada, Hideyuki
Yorinaga, Satoko
Shichinohe, Toshiaki
Tomaru, Utano
Komatsu, Yoshito
Hirano, Satoshi
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s40792-024-02001-w
- URN
-
urn:nbn:de:101:1-2411132059466.616372213823
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:37 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Toji, Yuta
- Takeuchi, Shintaro
- Ebihara, Yuma
- Kurashima, Yo
- Harada, Kazuaki
- Hayashi, Mariko
- Abe, Hirotake
- Wada, Hideyuki
- Yorinaga, Satoko
- Shichinohe, Toshiaki
- Tomaru, Utano
- Komatsu, Yoshito
- Hirano, Satoshi
- SpringerLink (Online service)
Other Objects (12)
The real-world efficacy and safety of nivolumab plus chemotherapy in patients with HER2-negative advanced gastric cancer
New HER2-negative breast cancer subtype responsive to anti-HER2 therapy identified
Immunotherapy for hormone receptor‒positive HER2-negative breast cancer
HER2-low breast cancer shows a lower immune response compared to HER2-negative cases
Phase Ib/II study of nivolumab combined with palliative radiation therapy for bone metastasis in patients with HER2-negative metastatic breast cancer
A phase 1b study of zilovertamab in combination with paclitaxel for locally advanced/unresectable or metastatic HER2-negative breast cancer
Pamiparib in patients with locally advanced or metastatic HER2-negative breast cancer with germline BRCA mutations: a phase II study
Single HER2-positive tumor cells are detected in initially HER2-negative breast carcinomas using the DEPArray™–HER2-FISH workflow
EndoPredict® in early hormone receptor-positive, HER2-negative breast cancer
Treatment of Advanced Hormone Receptor-Positive (HR+) HER2-negative Breast Cancer
Correction: a phase 1b study of zilovertamab in combination with paclitaxel for locally advanced/unresectable or metastatic HER2-negative breast cancer
The impact of HER2-low status on response to neoadjuvant chemotherapy in clinically HER2-negative breast cancer
The real-world efficacy and safety of nivolumab plus chemotherapy in patients with HER2-negative advanced gastric cancer
New HER2-negative breast cancer subtype responsive to anti-HER2 therapy identified
Immunotherapy for hormone receptor‒positive HER2-negative breast cancer
HER2-low breast cancer shows a lower immune response compared to HER2-negative cases
Phase Ib/II study of nivolumab combined with palliative radiation therapy for bone metastasis in patients with HER2-negative metastatic breast cancer
A phase 1b study of zilovertamab in combination with paclitaxel for locally advanced/unresectable or metastatic HER2-negative breast cancer
Pamiparib in patients with locally advanced or metastatic HER2-negative breast cancer with germline BRCA mutations: a phase II study
Single HER2-positive tumor cells are detected in initially HER2-negative breast carcinomas using the DEPArray™–HER2-FISH workflow
EndoPredict® in early hormone receptor-positive, HER2-negative breast cancer
Treatment of Advanced Hormone Receptor-Positive (HR+) HER2-negative Breast Cancer
Correction: a phase 1b study of zilovertamab in combination with paclitaxel for locally advanced/unresectable or metastatic HER2-negative breast cancer
The impact of HER2-low status on response to neoadjuvant chemotherapy in clinically HER2-negative breast cancer
The real-world efficacy and safety of nivolumab plus chemotherapy in patients with HER2-negative advanced gastric cancer
New HER2-negative breast cancer subtype responsive to anti-HER2 therapy identified
Immunotherapy for hormone receptor‒positive HER2-negative breast cancer
HER2-low breast cancer shows a lower immune response compared to HER2-negative cases
Phase Ib/II study of nivolumab combined with palliative radiation therapy for bone metastasis in patients with HER2-negative metastatic breast cancer
A phase 1b study of zilovertamab in combination with paclitaxel for locally advanced/unresectable or metastatic HER2-negative breast cancer
Pamiparib in patients with locally advanced or metastatic HER2-negative breast cancer with germline BRCA mutations: a phase II study
Single HER2-positive tumor cells are detected in initially HER2-negative breast carcinomas using the DEPArray™–HER2-FISH workflow
EndoPredict® in early hormone receptor-positive, HER2-negative breast cancer
Treatment of Advanced Hormone Receptor-Positive (HR+) HER2-negative Breast Cancer
Correction: a phase 1b study of zilovertamab in combination with paclitaxel for locally advanced/unresectable or metastatic HER2-negative breast cancer